Multi-Modality Therapy | Surviving Mesothelioma

Boosting Mesothelioma Survival with VEGF-Inhibitor

The VEGF inhibitor cediranib may not yet be out of the running as a mesothelioma treatment. Although previous studies have found it to have dose-limiting side effects, a new study in the Journal of Thoracic Oncology finds that, at the right dose, it could boost the effectiveness of standard mesothelioma chemotherapy. What is Cediranib? Cediranib, an oral drug made by Astra Zeneca, is a powerful … Continue reading Boosting Mesothelioma Survival with VEGF-Inhibitor »

Cholesterol Drug May Protect Mesothelioma Patients from Radiation

A new study suggests that the cholesterol-lowering drug pravastatin could one-day be used to help protect mesothelioma patients from the damaging side effects of radiotherapy. According to Japanese researchers, mice with malignant mesothelioma who were given pravastatin (Pravachol) in drinking water prior to receiving radiation experienced less damage to healthy cells in their lungs and intestines. The results suggest that pravastatin might make radiotherapy safer … Continue reading Cholesterol Drug May Protect Mesothelioma Patients from Radiation »

Altered Viruses May Help Boost Immunotherapy for Malignant Mesothelioma

Viruses may soon be playing a bigger role in the fight against malignant mesothelioma and other thoracic cancers. A pair of biologists from Minnesota say there is evidence that, in addition to killing mesothelioma cells directly, specific kinds of altered viruses might help make mesothelioma immunotherapy treatment more effective. How Does Immunotherapy Work? Like many other types of cancer, mesothelioma tumors are able to grow unchecked … Continue reading Altered Viruses May Help Boost Immunotherapy for Malignant Mesothelioma »

Standardization Needed for Peritoneal Mesothelioma Treatment

Mesothelioma researchers in Belgium and the US have some good news and some bad news about peritoneal mesothelioma treatment. The good news is that the combination of cytoreductive surgery to remove the mesothelioma tumor and intraperitoneal chemotherapy (HIPEC) to kill residual cancer cells improves mesothelioma survival. Overall, the method is so effective that the authors say the combination should now be considered standard of care … Continue reading Standardization Needed for Peritoneal Mesothelioma Treatment »

Immunotherapy and Radiation: A Powerful Mesothelioma Combo

New research suggests that, in the battle against malignant pleural mesothelioma, a treatment combining of immunotherapy drugs with radiotherapy may be a powerful new weapon. Researchers at the University of Pennsylvania reached that conclusion after reviewing the few existing studies on this emerging multimodal mesothelioma treatment for an article in Translational Lung Cancer Research.   Current available treatments for pleural mesothelioma, an aggressive lung-related cancer,  include surgical resection, … Continue reading Immunotherapy and Radiation: A Powerful Mesothelioma Combo »

IMRT Beats Conformal Radiotherapy for Pleural Mesothelioma

The targeted radiotherapy technique known as intensity-modulated radiotherapy (IMRT) may offer a safer way to treat pleural mesothelioma tumors with fewer side effects. Researchers at Gazi University in Ankara, Turkey recently compared the outcomes of  twenty-four radiation therapy plannings in patients with malignant pleural mesothelioma and found that IMRT was both less dangerous and more effective. Radiotherapy for Mesothelioma Radiotherapy is often used in pleural … Continue reading IMRT Beats Conformal Radiotherapy for Pleural Mesothelioma »

New Report May Fuel Debate Over Mesothelioma Surgery

A new Swiss report on the two major types of mesothelioma surgery appears to raise as many questions as it answers, adding fuel to the fire in the ongoing debate over surgical technique. While thoracic surgeons around the world remain divided over the best type of surgery for the asbestos cancer,  the report suggests that the two primary curative approaches have similar rates of complications … Continue reading New Report May Fuel Debate Over Mesothelioma Surgery »

VEGF-Inhibitor Looks Promising for Malignant Mesothelioma

There is more encouraging news about the monoclonal antibody bevacizumab (Avastin) and its potential to boost the effectiveness of chemotherapy for people with malignant pleural mesothelioma. A pair of oncology researchers from Texas have just released their summary of the the most recent published studies on bevacizumab. They conclude that, for the right patients, bevacizumab may improve mesothelioma outcomes and extend survival by blocking tumor blood … Continue reading VEGF-Inhibitor Looks Promising for Malignant Mesothelioma »

Additional Chemotherapy Extends Survival in Relapsed Mesothelioma Patients

Black American Patient

Mesothelioma patients who experience a recurrence of their asbestos cancer after radical surgery may live longer if they undergo additional rounds of chemotherapy. That conclusion comes from a group of Japanese researchers who performed a retrospective review of 59 consecutive pleural mesothelioma patients who had multimodal mesothelioma treatment that included extrapleural pneumonectomy (EPP) surgery. Study subjects had been treated for malignant mesothelioma at Hyogo College … Continue reading Additional Chemotherapy Extends Survival in Relapsed Mesothelioma Patients »

New Evidence Supports Post-Surgical IMRT for Mesothelioma Treatment

Just a week after New York researchers published their own study on radiation therapy and mesothelioma surgery, a group of doctors from Texas has reached a similar conclusion – that highly-targeted radiotherapy can improve mesothelioma survival. This week’s study was conducted by radiation oncology specialists at Austin Cancer Centers and Baylor Scott and White Health in Temple, Texas. The team performed a retrospective analysis of 18 … Continue reading New Evidence Supports Post-Surgical IMRT for Mesothelioma Treatment »

Get your free copy of
“Surviving Mesothelioma” Today!